Sandy Griffith

2.5k citations
18 papers · 525 · h-index 10

Impact in

  • Virology top 2%
    • HIV Research and Treatment
  • Infectious Diseases top 5%
    • HIV/AIDS drug development and treatment
    • HIV/AIDS Research and Interventions

Papers in

  • Infectious Diseases 13
    • HIV/AIDS drug development and treatment 12
    • HIV/AIDS Research and Interventions 6
  • Virology 8
    • HIV Research and Treatment 8
Co-authors
William Spreen (10 shared papers)Krischan J Hudson (7 shared papers)Susan L. Ford (3 shared papers)Kimberly Y. Smith (2 shared papers)Peter Williams (2 shared papers)Joseph J. Eron (1 shared paper)David M. Margolis (9 shared papers)Cynthia Brinson (1 shared paper)
Journals
Open Forum Infectious Diseases (6 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (2 papers)AIDS and Behavior (2 papers)British Journal of Clinical Pharmacology (1 paper)The Lancet Infectious Diseases (1 paper)
Partner nations
United StatesBelgiumCanada

In The Last Decade

Sandy Griffith

17 papers receiving 511 citations

Peers

Sandy Griffith
Comparison fields: 5 of 50
  • Virology 220
  • Infectious Diseases 372
  • Emergency Medicine 51
  • Epidemiology 77
  • Hepatology 17
Replace Prattana Leenasirimakul with:
Prattana Leenasirimakul Thailand
Mark Becker United States
Janet Nicotera United States
Debbie Hagins United States
Ashwaq Hermes United States
Linda Akagi Canada
Naomi Givens United Kingdom
Miguel Goicoechea United States
Clarisse Amani‐Bosse Ivory Coast
Rodica Van Solingen‐Ristea United States
Sandy Griffith relative to Prattana Leenasirimakul Thailand Prattana Leenasirimakul's profile →
Citations per field
00.5×2×4×6×8.7×
Prattana Leenasirimakul · 1×
Citations per year

Countries citing papers authored by Sandy Griffith

Since Specialization
Citations

This map shows the geographic impact of Sandy Griffith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandy Griffith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandy Griffith more than expected).

Fields of papers citing papers by Sandy Griffith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandy Griffith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandy Griffith. The network helps show where Sandy Griffith may publish in the future.

Co-authors

The 25 scholars most cited alongside Sandy Griffith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sandy Griffith Line = papers co-authored together Sandy Griffith links everyone, so they are left out of the graph.

All Works

18 of 18 papers shown
#Work
1
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
The Lancet Infectious Diseases ·David A. Margolis, Cynthia Brinson, Graham Smith, Jerome De Vente, Debbie Hagins, Joseph J. Eron, Sandy Griffith, M H St Clair, Marita Stevens, Peter Williams, Susan L. Ford, Britt Stancil, M Bomar, Krischan J Hudson, Kimberly Y. Smith, William Spreen
2015164
2
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
The Lancet HIV ·Chloe Orkin, Enrique Bernal, Darrell H. S. Tan, Harold Katner, Hans‐Jürgen Stellbrink, Elena Belonosova, Rebecca DeMoor, Sandy Griffith, Shanker Thiagarajah, Rodica Van Solingen‐Ristea, Susan L. Ford, Herta Crauwels, Parul Patel, Amy Cutrell, Kimberly Y. Smith, Kati Vandermeulen, Eileen Birmingham, Marty St. Clair, William Spreen, Ronald D’Amico
202190
3
Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine
JAIDS Journal of Acquired Immune Deficiency Syndromes ·John Bartlett, Judy Johnson, Gisela Herrera, Néstor Sosa, Alan Rodriguez, Qiming Liao, Sandy Griffith, David M. Irlbeck, Mark S. Shaefer
200656
4
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
AIDS and Behavior ·Miranda Murray, Antonio Antela, Anthony Mills, Jenny Huang, H. de Jager, Enrique Bernal, Johan Lombaard, Harold Katner, Sharon Walmsley, Marie-Aude Khuong-Josses, Krischan J Hudson, David Dorey, Sandy Griffith, William Spreen, Simon Vanveggel, Mark S. Shaefer, David M. Margolis, Vasiliki Chounta
202055
5
Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects
British Journal of Clinical Pharmacology ·Ann K. Miller, Emma Harrell, Ye Li, Sharon Baptiste‐Brown, Jőrg‐Peter Kleim, Colin Ohrt, Stephan Duparc, Jörg J. Möhrle, Alison Webster, Sandra S. Stinnett, Arlene R. Hughes, Sandy Griffith, Andrew P. Beelen
201342
6
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials
AIDS and Behavior ·Andrea Mantsios, Miranda Murray, Tahilin Sanchez Karver, Wendy Davis, David M. Margolis, Princy Kumar, Susan Swindells, U. Fritz Bredeek, Miguel García Deltoro, Mercedes García‐Gasalla, Rafael Rubio, Antonio Antela, Krischan J Hudson, Sandy Griffith, Deanna Kerrigan
202036
7
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study
PubMed ·Miranda Murray, Federico Pulido, Anthony Mills, Moti Ramgopal, Roger LeBlanc, Hans Jaeger, (unknown), David Dorey, Sandy Griffith, Joseph Mrus, William Spreen, David M. Margolis
201926
8
2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies
Open Forum Infectious Diseases ·Parul Patel, Susan L. Ford, Herta Crauwels, Kelong Han, Stefaan Rossenu, Martine Neyens, Sandy Griffith, Krischan J Hudson, David M. Margolis, Mark Baker, Peter Williams, William Spreen
201917
9
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
BMC Infectious Diseases ·Jeffrey P. Nadler, Joseph Gathe, Richard B. Pollard, Gary Richmond, Qiming Liao, Sandy Griffith, C. Tracey Lancaster, Jaime E. Hernández, Keith A. Pappa, (unknown)
200311
10
P032: Dolutegravir versus raltegravir in ARV-experienced INI-naïve HIV+ adults: 48-week subgroup analysis of Latin American subjects in the SAILING study
Journal of the International AIDS Society ·Pedro Cahn, Jaime Andrade‐Villanueva, Carlos Beltrán, Tâmara Newman, David Dorey, Dannae Brown, Isidoro Prudente, Sandy Griffith, Michael Aboud, Carlos Fernando de Oliveira
20159
11
884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies
Open Forum Infectious Diseases ·Paula Teichner, Amy Cutrell, Ronald D’Amico, David Dorey, Sandy Griffith, Conn Harrington, Jenny Huang, Krischan J Hudson, David M. Margolis, Joseph Mrus, Joseph W. Polli, William Spreen, Peter Williams, Rodica Van Solingen‐Ristea, Mark S. Shaefer
20194
12
1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results
Open Forum Infectious Diseases ·Vasiliki Chounta, Enrique Bernal, Johan Lombaard, Harold Katner, Sharon Walmsley, David Dorey, William Spreen, Sandy Griffith, David M. Margolis
20204
13
1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome
Open Forum Infectious Diseases ·Christine L. Talarico, Sterling Wu, Ojesh R Upadhyay, Marty St. Clair, Veerle Van Eygen, Krischan J Hudson, Sandy Griffith, Conn Harrington, Jan van Lunzen, David M. Margolis, William Spreen
20204
14
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Maggie Czarnogorski, Paul Benn, Cindy McCoig, Toyin Nwafor, Sandy Griffith, Ken Sutton, Conn Harrington, Parminder Saggu, Itziar Yague, Will Williams, Carlos Martín Español, Jessica Goodchild, Jane Fricker, Parul Patel, Ronald D’Amico
20222
15
LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials
Open Forum Infectious Diseases ·Ronald D’Amico, Paul Benn, Cynthia McCoig, Sandy Griffith, Krischan J Hudson, Kenneth Sutton, Conn Harrington, Sterling Wu, Will Williams, Kai Hove, Carlos Martín Español, E Jane Fricker, Parul Patel, David M. Margolis
20202
16
1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies
Open Forum Infectious Diseases ·Paula Teichner, Sterling Wu, Feifan Zhang, David Dorey, Ronald D’Amico, Sandy Griffith, Kenneth Sutton, Cynthia McCoig, Ojesh R Upadhyay, Joseph W. Polli, David M. Margolis, Rodica Van Solingen‐Ristea, Kati Vandermeulen, William Spreen, Parul Patel
20202
17
A prospective, multicenter, open-label, clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for treatment of unresectable hepatocellular carcinoma (HCC): DOORwaY90
HPB ·Armeen Mahvash, Suzanne Chartier, Marco Rosselli Del Turco, P. Habib, Sandy Griffith, Sheldon T. Brown, S. Cheenu Kappadath
20211
18
The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans
Southern African Journal of HIV Medicine ·Rosie Mngqibisa, Yogita Singh, Catherine Orrell, Johan Lombaard, Sandy Griffith, Conn Harrington, Ronald D’Amico, William Spreen, Marty St Clair, Christine L. Latham, Louise Garside, Rodica Van Solingen‐Ristea, Veerle Van Eygen, Fafa Addo Boateng, Herta Crauwels, Prosperity Eneh, Ingrid Eshun‐Wilson
20250

About Sandy Griffith

Sandy Griffith is a scholar working on Infectious Diseases, Virology, Hepatology, Epidemiology and Pediatrics, Perinatology and Child Health, having authored 18 papers that have together received 525 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (8 papers), HIV/AIDS Research and Interventions (6 papers), Hepatitis C virus research (2 papers), Pneumocystis jirovecii pneumonia detection and treatment (1 paper), Cancer Genomics and Diagnostics (1 paper), Advanced Radiotherapy Techniques (1 paper) and HIV, Drug Use, Sexual Risk (1 paper). The work is most often cited by research in Virology (220 citations), Infectious Diseases (372 citations), Emergency Medicine (51 citations), Epidemiology (77 citations) and Hepatology (17 citations). Sandy Griffith has collaborated with scholars based in United States, Belgium and Canada. Frequent co-authors include William Spreen, Krischan J Hudson, Susan L. Ford, Kimberly Y. Smith, Peter Williams, Joseph J. Eron, David M. Margolis, Cynthia Brinson, Britt Stancil and Mark S. Shaefer. Their work appears in journals such as Open Forum Infectious Diseases, JAIDS Journal of Acquired Immune Deficiency Syndromes, AIDS and Behavior, British Journal of Clinical Pharmacology and The Lancet Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Prattana LeenasirimakulBreakdown of academic impact, for papers by Mark BeckerBreakdown of academic impact, for papers by Janet NicoteraBreakdown of academic impact, for papers by Debbie HaginsBreakdown of academic impact, for papers by Ashwaq HermesBreakdown of academic impact, for papers by Linda AkagiBreakdown of academic impact, for papers by Naomi GivensBreakdown of academic impact, for papers by Miguel GoicoecheaBreakdown of academic impact, for papers by Clarisse Amani‐BosseBreakdown of academic impact, for papers by Rodica Van Solingen‐Ristea